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1. Introduction
Diabetes is the most common complication of gestation, and this condition is associated
with a higher frequency of maternal and fetal complications. Gestational diabetes mellitus
(GDM), defined as glucose intolerance with onset or first recognition in pregnancy that is
not clearly overt diabetes (ADA, Standards of Medical Care, 2013), is responsible for the ma‐
jority of these complications and affects 1–14% of all pregnancies, becoming a growing
health concern (Albrecht et al, 2010). Although diabetes types 1 and 2 are proportionally
smaller contributors to this problem, the prevalence of pregnancies complicated by preges‐
tational diabetes is rising as a result of certain environmental risk factors and the exponen‐
tial increase in obesity (Wendland et al, 2011).
There is a well-documented relationship between a good glycemic control in healthy or dia‐
betic pregnant women and lower rates of congenital malformations and perinatal complica‐
tions (Ballas et al, 2012). On the other hand, despite the increasing number of pregnant
women with diabetes, there has been a gradual decline in the amount of attention paid by
specialists to the follow-up of these patients, and the dwindling economic resources allocat‐
ed to public health services mean that access to specialized healthcare facilities is becoming
more difficult. Attending a metabolic care unit can prove difficult for other reasons too (e.g.
for women living too far away, or with no independent means of transportation, or needing
© 2013 Chilelli et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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to rest to avoid preterm delivery). In this complex and worrying scenario, exploiting new
technologies may be a ploy to ensure the effective management of these patients.
Telemedicine, or the use of information and communication technology (ICT) to provide
medical care at a distance, is one such opportunity, in its various applications that differ
mainly in terms of the mode of interaction, the monitoring method, and the types of device
involved (Klonoff DC, 2012).
The basic principle behind telemedicine is to use ICT to facilitate the interaction between
health professionals and patients. The current inability to assure certain patients a regular,
direct contact with their healthcare providers can be offset by using telemedicine applica‐
tions, teleconsultations and videoconferencing. Using telemedicine to support pregnant
women with diabetes could have an impact not only on the classical maternal-fetal out‐
comes, but also on other aspects not always taken into due account in the management of
these patients, i.e. their quality of life, their perception of the effectiveness of care ("diabetes
self-efficacy"), and their glycemic variability (Mastrogiannis et al, 2013).
Little research has been conducted on the impact of telemedicine systems on clinical out‐
comes in women with pregnancies complicated by diabetes. In this chapter we analyze the
currently available evidence regarding the use of telemedicine in this scenario (Table 1 and
Table 2), trying to highlight the main limitations of the trials performed to date and possible
strategies to overcome them with a view to improving the efficacy of future clinical inter‐










Wójcicki JM, 2001 15/15 ↑/nv nv nv
Ładyżyński P, 2001 15/nv ↑/nv ↑ nv
Ładyżyński P, 2007 15/15 =/↑ nv nv
Di Biase N, 1997 10/10 ↑/nv nv nv
Frost D, 2000 11/10 ↑/nv nv nv
Dalfrà MG, 2009 17/15 =/↑ ↑ nv
For more details about the "clinical, behavioral and care coordination" outcomes, refer to Verhoeven et al, 2010
Table 1. Brief summary of the main outcomes of the studies conducted in pregnants with type 1 diabetes. QoL:











Pérez-Ferre N, 2009 49/48 =/nv nv ↑
Pérez-Ferre N, 2010 49/48 =/↑ ↑ ↑
Homko CJ, 2007 32/25 =/↑ ↑ nv
Homko CJ, 2012 40/40 =/↑ ↑ nv
Dalfrà MG, 2009 88/115 ↑/↑ ↑ nv
For more details about the "clinical, behavioral and care coordination" outcomes, refer to Verhoeven et al, 2010
Table 2. Brief summary of the main outcomes of the studies conducted in pregnants with GDM. QoL: quality of life;
nv: not valued
2. Goals of telemedicine: pregnancy and fetal outcome
Maternal hyperglycemia prompts the passage of more glucose to the fetus, causing fetal hy‐
perinsulinemia and an overgrowth of insulin-sensitive (especially adipose) tissue, which
lead to an unbalanced growth of the fetus and the consequent risk of greater trauma at birth,
shoulder dystocia and perinatal death. Hyperinsulinemia can also cause numerous neonatal
metabolic complications, such as hypoglycemia, hyperbilirubinemia, hypocalcemia, hypo‐
magnesemia, polycythemia, respiratory distress syndrome, and a higher long-term risk of
diabetes mellitus and obesity in the child. Diabetes in pregnancy is related to maternal com‐
plications too, such as hypertension, pre-eclampsia, a greater need for caesarean delivery,
and a higher risk of developing diabetes mellitus later on. Pregnancy complicated by obesity
is characterized by higher adverse maternal and fetal outcome rates too, especially in GDM
patients (Lapolla et al, 2009). Education for women at risk and regular visits to an antenatal
clinic are important potential modifiers of most of these factors.
In this setting, the HAPO Study enrolled more than 23,000 women attending 15 antenatal
centers all over the world, considerably improving our understanding and demonstrating
that even mild degrees of hyperglycemia in pregnancy are associated with increased fetal
fatness, cesarean delivery and neonatal hypoglycemia, all against a background of a bio‐
logical  increase in fetal  insulin production.  The HAPO study was supported by two re‐
cent randomized trials (Crowther CA, 2005; Landon MB, 2009) confirming that treatment
for mild hyperglycemia (largely by means of changes in lifestyle) is effective in improv‐
ing a number of maternal and fetal outcomes. In both the latter trials, birth weights and
the  frequency  of  large  for  gestational  age  (LGA)  babies  and  pre-eclampsia  were  all  re‐
duced by treatment (McCance DR, 2011).
The best approach to women with pregnancies complicated by diabetes is therefore inten‐
sive, involving frequent glucose self-monitoring and dietary restrictions and/or adequate in‐
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sulin therapy (Landon MB, 2011). Using telemedicine can facilitate the management of
pregnancy complicated by diabetes, being applicable to all the above-mentioned areas of in‐
tervention. The great challenge now is to demonstrate the efficacy of this innovative tool in
terms of maternal-fetal outcome and an advantageous cost/benefit ratio.
3. Telemedicine and its applications to diabetes care in pregnancy
The main applications of telemedicine relate to educating patients to manage their chronic
diseases, making it easier for them to contact their healthcare providers, and enable the col‐
lection of information and its transfer to clinical databases. ICT can help in the management
of diabetic patients by providing additional clinical support, which is now increasingly diffi‐
cult to achieve in the classical face-to-face interaction due to the limited health resources
available (Lapolla A, 2011). The most encouraging technology nowadays is teleconsultation,
involving telemonitoring schemes that include asynchronous exchanges between patients
and their healthcare providers (e.g. e-mails, text messages on mobile phones, automated
messaging, or other methods requiring no face-to-face contact), or synchronous communica‐
tions in the form of face-to-face contact using videoconferencing equipment (television, digi‐
tal camera, webcam, videophone) to connect healthcare providers to one or more patients at
the same time, also for the purpose of providing education and training (Kern J, 2006).
These systems are designed basically as a means to improve the quality of care through clos‐
er communications between patients and professionals, in an effort to create a more dynam‐
ic and motivating exchange, involving patients to a greater extent in their own care, and
making the monitoring of their disease more compatible with their lifestyle (Verhoeven F,
2007; McMahon GT, 2005). This applies in particular to the management of diabetes (Franc
S, 2011) and especially in pregnancy complicated by diabetes, given the drastically reduced
time available for examining and educating these patients who need short-term adjustments
to their therapy and reassurance concerning an appropriate diet, as well as routine care (La‐
polla et al, 2011). Combining the applications of telemedicine with programs for managing
diabetes in pregnancy seems to be a fundamental step to combine the need for an intensive
approach to these patients with the containment of the associated costs.
Studies evaluating these applications must take into account both clinical aspects, including
those related to the effects on quality of life, both behavioral outcomes and finally economic/
social issues, especially related to health care costs (Verhoeven F et al, 2010).
3.1. Evidence of the use of telemedicine in pregnant women with type 1 diabetes
Wojcicki et al analyzed the effectiveness of an automated telematic intensive care system for
transferring all of patients’ glucose measurements taken during the course of a day to a cen‐
tral clinical unit. The patients’ mean blood glucose (MBG) and an indicator of glucose varia‐
bility (the J-index) were used to monitor their glycemic control. The authors demonstrated a
better glycemic control in the experimental group by comparison with a control group,
based on the average differences in the patients’ MBG and J indices, calculated weekly
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(ΔMBG = -3.2 +/- 4.3 mg/dL, p = 0.0016, ΔJ = -1.4 +/- 2.3, p = 0.0065). They also found a ten‐
dency for a better glycemic control in patients with a lower intelligence quotient (IQ < 100)
supported by the telematic system by comparison with all the other groups of patients,
though this difference lacked statistical significance. The telematic intensive care system im‐
proved the efficacy of diabetes treatment during pregnancy (Wójcicki JM, 2001).
Ladyzynsky et al developed a system for supporting intensive insulin treatment in pregnant
women with type 1 diabetes. The system consists of a patient teletransmission module
(PTM) and a central clinical control unit (CCU). The PTM comprises a box containing a
blood glucose meter and an electronic logbook, a modem for dial-up internet or a cellular
phone set. The CCU consists of a PC with a modem and DIAPRET software – a dedicated
program designed to monitor the intensive insulin treatment. The system was tested on 15
pregnant type 1 diabetic women for 166±24 days. Its total effectiveness was 69.3±13.0% and
its technical effectiveness was 91.5±6.1%, and was not significantly influenced by the pa‐
tients’ IQ, formal education or place of residence, while it turned into a better metabolic con‐
trol (Ładyżyński et al, 2001).
The same authors also assessed the influence of the greater frequency of data reporting on
diabetic patients’ metabolic control. Data were reported via a home telecare system that
stored blood glucose levels and was integrated with a simple electronic logbook. The data
collected by patients were automatically transmitted via the telephone network every night.
The study population consisted of 30 patients with type 1 diabetes, who were randomly al‐
located to the home telecare group or a control group. The control group’s treatment was
based on clinical examinations performed every three weeks. For the home telecare group,
the data recorded by patients were transmitted to the hospital daily, enabling doctors to in‐
tervene more frequently. The average duration of the study was 180 days (standard devia‐
tion, SD 22) in the home telecare group and 176 days (SD 16) in the control group. The mean
level of metabolic control and the insulin dose adjustment patterns were very similar in the
two groups despite the much greater (15-fold) reporting frequency in the home telecare
group. The data collected by patients were not fully usable, mainly because of an excessively
high within-day variability in glycemic control and the high workload for the hospital staff
performing the daily data analysis. On average, for the home telecare group, the patients’
data were collected about 0.7 times per day (i.e. 15 times more often than in the case of rou‐
tine treatment), although average metabolic control was found only slightly better for the
home telecare group than for controls, and the number of adjustments to patients’ insulin
doses was very similar in the two groups. Both general compliance issues (relating to the
considerable effort needed to analyze the daily data) and clinical problems (e.g. a high intra-
day glycemic variability) probably contributed to the lack of any significant differences be‐
tween the two groups. These findings prompted the authors to conclude that remote
systems used at home by patients with type 1 diabetes on intensive insulin therapy im‐
proves their glycemic control, but needs to support real-time data transmission and be com‐
bined with appropriate data analysis and subsequent decision-making for it to achieve any
real improvement in the quality of care (Ładyżyński et al, 2007).
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Di Biase et al also investigated whether telemedicine could be useful in the management of
pregnant type 1 diabetic women. A fully automated system (the DIANET system) was used
and 20 type 1 pregnant women took part in the study: 10 were treated using the telemedi‐
cine system, the other 10 using the conventional approach. The DIANET system was adopt‐
ed at 4 different times, termed as: “entry” (at 9.5 weeks of gestation); “basal” (9.5-16.8
weeks); “1st month” of investigation; and “end” (near delivery). All the women adopted in‐
tensified insulin administration protocols. Judging from the profiles of the women’s abso‐
lute blood glucose values, the DIANET ensured a better metabolic control than the
conventional approach. These results were associated with higher insulin doses being used
by the women in the DIANET group. There was a significant reduction in both groups’ hy‐
poglycemic episodes at the “end”, “1st month” and “basal” study points by comparison with
the situation at “entry”. Based on their results, the authors suggest that telemedicine (DIA‐
NET) is a practical way to provide specialist care in pregnancy (Di Biase et al, 1997)
Frost et al used a remote data management system (CareLink; Abbott-MediSense, New Bed‐
ford, MA) to monitor 11 pregnant women with type 1 diabetes (all on intensive insulin ther‐
apy) from the 15th gestational week onwards, comparing them with controls receiving
routine diabetes care, which consisted of visits every 2-3 weeks. The controls were 10 preg‐
nant women with type 1 diabetes matched for age, history of diabetes, and expertise with
self-monitoring and insulin regimens. The average time between two visits was 3.3 weeks
for the CareLink group and 2.9 weeks for the control group. There was an improvement in
HbA1c in both the CareLink group (from 6.1±1.0 to 5.4±0.3) and the control group (from
6.2±0.8 to 5.7±0.6), though the differences were not statistically significant. MBG levels drop‐
ped in the CareLink group from 141±90 to 110±18 mg/dl, and fasting glucose from 111±17 to
101±23 mg/dl (p <0.05). Glycemic variability was also significantly reduced in both groups:
the standard deviation of the MBG levels in individual patients fell from 51.6 to 44.4 mg/dl
(p <0.01), while for mean fasting blood glucose the SD decreased from 41.4 to 31.0 mg/dl.
There was no significant reduction in the number of hypoglycemic episodes in either of the
groups. The authors concluded that the system was easy to use and helpful in the treatment
of diabetic women during pregnancy, enabling fewer outpatient visits. This aid would
therefore be particularly suitable for women who have difficulty attending the prescribed
regular check-ups at the clinic (Frost et al, 2000).
3.2. Evidence of the use of telemedicine in pregnant women with GDM
Dalfrà et al enrolled a total of 235 pregnant women (203 with GDM and 32 with type 1 dia‐
betes mellitus) and assigned them sequentially to a telemedicine or a control group. Women
with type 1 diabetes were enrolled in the study immediately after conception, while women
with GDM were included one week after their GDM was diagnosed (at a mean 28±1 weeks
of gestation). The pregnant women in the telemedicine group were trained to monitor their
blood glucose levels with a glucometer (One Touch Ultra-Lifescan) and send their blood
glucose profiles to Glucobeep by means of a standard phone call. These women also attend‐
ed 1 outpatient visit per month. The women in the control group only had a medical exami‐
nation every two weeks. All patients could contact the physician whenever they wished.
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Clinical and non-clinical outcomes were evaluated: the former included mode and timing of
delivery, macrosomia, maternal and fetal morbidity; the latter were deduced using question‐
naires, i.e. the CES-D for depression, the SF-36 for health-related quality of life (QoL), the
Stress and Distress or the impact of diabetes. The telemedicine GDM group achieved a bet‐
ter metabolic control in the third trimester (p=0.008) and a lower rate of cesarean sections
(p=0.02) and macrosomia (p=n.s.). The women in the telemedicine group also had lower lev‐
els of frustration and concern about their diabetes, and a better acceptance of their diabetic
condition. A strength of this study lies in that the authors adopted a straightforward teleme‐
dicine system (using the telephone) that was easy for all patients to handle, demanding no
IT expertise or computer literacy (Dalfrà et al, 2009).
Pèrez-Ferre et al studied 97 women with GDM to ascertain the feasibility of a telemedicine
system based on the Internet and text messaging, and its influence on delivery and neonatal
outcomes (HbA1c values < 5.8%, normal vaginal deliveries, and LGA babies). Forty-eight
women attended traditional face-to-face visits and 49 formed the experimental group using
the telemedicine system to send capillary glucose data and short text messages, receiving
professional feedback weekly. There was no significant difference between the two groups
in terms of the outcomes considered, despite the experimental group’s significantly reduced
number of visits to the clinic, particularly among the insulin-treated women. The authors
concluded that the telemedicine-based system achieved similar pregnancy, delivery and
newborn outcomes to the traditional treatment approach, while significantly reducing the
need for outpatient clinic visits (Pérez-Ferre N, 2009)
More recently, the same authors demonstrated that, compared with a control group, a tele‐
medicine group reduced the number of unscheduled face-to-face visits by 62% (and by
82.7% for the subgroup of insulin-treated patients), improving patient satisfaction and ach‐
ieving comparable pregnancy and newborn outcomes (Pérez-Ferre N, 2010).
In a study by Homko et al, women with GDM were randomized to either an Internet group
(n = 32) or a control group (n = 25). Patients in the Internet group were given computers
and/or Internet access as necessary. A website was established for recording glucose levels
and for communications between patients and the health care team. Women in the control
group kept paper logbooks, which were reviewed at each prenatal visit. Maternal feelings
about diabetes self-efficacy were assessed at study entry and again before delivery. Women
in the Internet group accessed the system and sent a mean 21.8 (±16.9) sets of data. There
was no difference between the two groups’ fasting or post-prandial blood glucose levels, al‐
though more women in the Internet group were on insulin therapy (31% vs. 4%; P <0.05).
There were also no significant differences in pregnancy and neonatal outcomes between the
two groups. The women in the Internet group demonstrated a significantly stronger sense of
self-efficacy at the end of the study. The potential benefits of monitoring blood glucose via
the Internet in indigent women with GDM was limited by their infrequent use of the teleme‐
dicine system. While using the system was not associated with better pregnancy outcomes,
the diabetic women in the telemedicine group did experience a better sense of psychosocial
self-efficacy (Homko CJ, 2007).
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In a subsequent study, these authors tested a more advanced telemedicine system, which in‐
cluded automated reminders to patients to send their data. Eighty GDM women were
randomized to join an intervention group using telemedicine to send blood glucose record‐
ings obtained 4 times a day via the Internet or telephone, or a control group using paper log‐
books. Although there were no significant differences in the outcomes considered (glucose
control and birth weight of offspring), this type of telemedicine approach improved the con‐
tact between patients and healthcare professionals, making the use of technology for moni‐
toring of diabetes in pregnancy more familiar (Homko CJ, 2012).
Finally, in GDM patients one study showed that integrating telemedicine applications and
involvement of the nursing staff turns into better fetal outcome and adhesion to glucose
monitoring. With this respect Ferrara et al demonstrated that higher referral frequency to
telephonic nurse management for gestational diabetes mellitus decreased risk of macroso‐
mic infant and increased postpartum glucose testing (Ferrara et al, 2012).
4. Conclusion
Recent reports in the literature have addressed several aspects of telemedicine applied to the
treatment of diabetes in pregnancy. The use of telemedicine appears to be not only feasible,
but also capable of achieving the same glycemic control and perinatal outcomes as conven‐
tional care, with fewer visits to the clinic. This would naturally be appreciated by patients,
but there is also the economic impact on the physician’s side to consider. Fewer visits to the
doctor would cut costs while assuring the same level of care, even after the costs of creating
a telemedicine system have been taken into account. If telemedicine applied to the treatment
of diabetes during pregnancy can benefit both parties (patients and doctors), it could drasti‐
cally change current treatment methods (ATTD 2010 Yearbook, 2011). The implementation
of telemedicine in the clinical management of GDM also supports the greater involvement
of figures, such as nurses and dietitians (Figure 1), whose support can help in saving time
and resources in the follow-up of these patients (García-Patterson, 2003).
The present review raises a number of questions about the intrinsic value of telemedicine in
the management of chronic disease. It would be useful if future studies were designed very
carefully in order to identify the true value of remote patient support systems. It would also
be valuable to future reviewers if a minimum dataset were adopted to measure outcomes.
Quantitative indices, from which pooled estimates of effect can be calculated, include:
• quality of life (measured on scales appropriate to the diseases in question);
• cost to society;
• emergency department visits;
• days in hospital.
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Finally, it seems unlikely that any intervention on chronic diseases can have much effect un‐
less it is applied over a lengthy period of time (Wootton R, 2012). Future studies might con‐
sider testing telemedicine schemes for years rather than months.
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